Foundayo Clears EMA's CHMP for Weight Management AND Type 2 Diabetes — a Broader EU Label Than the Wegovy Pill's
On Oct 15–16, 2026 the EMA's CHMP recommended EU marketing authorization for Lilly's Foundayo (orforglipron). From the EMA's own announcement: "EMA has recommended granting a marketing authorisation in the European Union for Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and treatment of type 2 diabetes in adults."
The dual indication is the competitive point: Novo's Wegovy pill won EU approval in July for weight management only, so Foundayo would enter Europe as the second oral GLP-1 but the first oral with a T2D claim — "putting the once-daily oral GLP-1 pill on course to become the second oral GLP-1 available in Europe and opening a new competitive front with Novo Nordisk1" (pharmaphorum). The EMA cited two pivotal weight-management studies in 4,740 adults (about 5–11% weight loss at 72 weeks by dose vs 2–2.5% on placebo) and four T2D studies in 3,765 adults (HbA1c cuts of 1.2–1.9 points, vs 1.2–1.5 for oral semaglutide 7/14 mg). Dosing convenience is Foundayo's calling card: "It can be taken at any time of day, with or without food" — versus the Wegovy pill's empty-stomach regimen.2 The European Commission typically rules within a few weeks; pricing is then set member state by member state.
The US oral battle settled into a two-horse pattern (Fierce Pharma Oral GLP-1 Tracker, Oct 16 update, IQVIA via Citi/Jefferies): Wegovy pill ~173.5K weekly scripts (-3% seq), Foundayo 60,151 (+4%, still shy of its 64,268 record set the week of Oct 2), Zepbound flat at ~801.8K, all-Wegovy down 2.5% to 492.6K. Jefferies models $208M of Q3 Foundayo revenue, "in line with consensus." Late in September Lilly cut self-pay pricing on the initial Foundayo doses to $149/$149/$199 per month (0.8/2.5/5.5 mg) — framed per Leerink as "an elasticity experiment and as a push to the first maintenance dose."
On the tracked threshold: Foundayo's ~60.2K scripts are ~26% of combined oral scripts (~233.7K) — the >30% oral-market-share watch has not fired.
Meaning: Foundayo now has the broader label in Europe and the convenience story, while Novo keeps the brand/familiarity edge in the US oral market. With Novo's Jan 1, 2027 $675 list-price cut coming (see Novo Into the Q3 Print: A 9x P/E, a DKK 15B Buyback, and a Stacked Q4 Catalyst Calendar), the EU launch and the pricing experiment give Lilly two more levers to press before year end. Lilly reports Q3 on Oct 29.
-
An instance of A multi-year head start collapses when a fast-follower delivers superior clinical efficacy. — The fast-follower's broader dual-indication label and dosing convenience erode Novo's first-mover European head start within months. ↩︎
-
An instance of Strict fasting rules strip the convenience benefit from oral peptide weight-loss drugs. — The food-flexible small molecule strips the fasting-constrained peptide pill of the convenience edge that anchored its oral position. ↩︎